Compare Incyte Corporation (INCY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Direxion Daily TSLA Bull 2X Shares trades at $8.02. The key difference: Incyte Corporation is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| INCY | TSLL | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $23.03 |
52-Week Low | $81.61 | $6.74 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $8.15, down 0.73% on the day, with technical indicators showing a bearish trend. The ETF, which aims to deliver twice Tesla's daily returns, faces challenges as recent news highlights volatility risks for leveraged Tesla investments. Key support sits at $8 with resistance at $9, while RSI levels suggest mixed momentum signals.
The outlook remains cautious given the bearish technical signals and leveraged structure amplifying Tesla's volatility. Investment opportunities exist for short-term traders betting on Tesla rebounds, but risks include magnified losses during downturns and the structural decay of daily reset leveraged ETFs in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
